CRISPR Therapeutics AG’s recently made public that its Director Treco Douglas A acquired Company’s shares for reported $1.14 million on Aug 06 ’25. In the deal valued at $57.03 per share,20,000 shares were bought. As a result of this transaction, Treco Douglas A now holds 22,000 shares worth roughly $1.31 million.
Then, George Simeon bought 989,812 shares, generating $51,499,918 in total proceeds. Upon buying the shares at $52.03, the Director now owns 1,730,179 shares.
Before that, Patel Naimish sold 3,932 shares. CRISPR Therapeutics AG shares valued at $141,316 were divested by the Chief Medical Officer at a price of $35.94 per share. As a result of the transaction, Patel Naimish now holds 6,068 shares, worth roughly $0.36 million.
Evercore ISI upgraded its CRISPR Therapeutics AG [CRSP] rating to an Outperform from a an In-line in a research note published on February 14, 2025; the price target was increased to $99 from $60. A number of analysts have revised their coverage, including TD Cowen’s analysts, who increased its forecast for the stock in mid February from “a Sell” to “a Hold”. H.C. Wainwright began covering CRSP with “Buy” recommendation on February 03, 2025. Needham maintained its rating on August 06, 2024. It rated CRSP as “a Buy”.
Price Performance Review of CRSP
On Friday, CRISPR Therapeutics AG [NASDAQ:CRSP] saw its stock jump 1.55% to $59.73. Over the last five days, the stock has gained 8.60%. CRISPR Therapeutics AG shares have risen nearly 23.87% since the year began. Nevertheless, the stocks have risen 51.75% over the past one year. While a 52-week high of $71.13 was reached on 07/21/25, a 52-week low of $30.04 was recorded on 04/07/25.
Levels Of Support And Resistance For CRSP Stock
The 24-hour chart illustrates a support level at 58.61, which if violated will result in even more drops to 57.50. On the upside, there is a resistance level at 61.14. A further resistance level may holdings at 62.56.
How much short interest is there in CRISPR Therapeutics AG?
A steep rise in short interest was recorded in CRISPR Therapeutics AG stocks on 2025-07-31, dropping by -2.1 million shares to a total of 23.45 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-30 was 25.54 million shares. There was a decline of -8.94%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on August 02, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $90 price target.
